

NCT02918409 Raw comparison:

Summary:
CHIA has 9 criteria while your personal folder has 18 criteria
Total found criteria: 8/9
Total not Found: 1/9
Total Extra: 9
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male or female = 18 years of age at Visit 1        │ Male or female ≥ 18 years of age at Visit 1        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Sweat chloride equal or greater than 60 mEq/L by   │ Sweat chloride equal or greater than 60 mEq/L by   │
│ quantitative pilocarpine iontophoresis test        │ quantitative pilocarpine iontophoresis test        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Two well-characterized mutations in the cystic     │ Two well-characterized mutations in the cystic     │
│ fibrosis transmembrane conductance regulator       │ fibrosis transmembrane conductance regulator       │
│ (CFTR) gene                                        │ (CFTR) gene                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Abnormal nasal potential difference (NPD) as       │ Abnormal nasal potential difference (NPD) as       │
│ measured by a change in NPD in response to a low   │ measured by a change in NPD in response to a low   │
│ chloride solution and isoproterenol of less than   │ chloride solution and isoproterenol of less than   │
│ -5 mV                                              │ -5 mV                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documentation of the presence of an acute          │ Documentation of the presence of an acute          │
│ pulmonary exacerbation based on CF Foundation      │ pulmonary exacerbation based on CF Foundation      │
│ guidelines as diagnosed by a faculty member of the │ guidelines as diagnosed by a faculty member of the │
│ Denver Adult CF Program                            │ Denver Adult CF Program                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Respiratory culture(s) demonstrating evidence of   │ Respiratory culture(s) demonstrating evidence of   │
│ Pseudomonas aeruginosa or Achromobacter species    │ Pseudomonas aeruginosa or Achromobacter species    │
│ airway infection                                   │ airway infection                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is able to produce sputum undergo          │ Subject is able to produce sputum undergo          │
│ phlebotomy and provide written consent             │ phlebotomy and provide written consent             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The subject's treating physician has determined    │ The subject's treating physician has determined    │
│ that they should receive either tobramycin or      │ that they should receive either tobramycin or      │
│ colistin intravenously as one of the designated    │ colistin intravenously as one of the designated    │
│ agents for their APE treatment Subjects who are    │ agents for their APE treatment Subjects who are    │
│ able to receive either tobramycin or colistin as   │ able to receive either tobramycin or colistin as   │
│ part of their antibiotic regimen will be           │ part of their antibiotic regimen will be           │
│ randomized into one of three arms If a treating    │ randomized into one of three arms If a treating    │
│ physician deems that a subject cannot receive      │ physician deems that a subject cannot receive      │
│ tobramycin due to vestibular toxicity ototoxicity  │ tobramycin due to vestibular toxicity ototoxicity  │
│ or bacterial resistance the subject will be        │ or bacterial resistance the subject will be        │
│ randomized to either standard or PK-adjusted       │ randomized to either standard or PK-adjusted       │
│ colistin                                           │ colistin                                           │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal   │
╞═══════════════════════════════════════╡
│ NA                                    │
╘═══════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                             │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Presence of chronic renal insufficiency with abnormal baseline creatinine \>1 2mg/dL                │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patients being treated for B cepacia due to colistin resistance by the pathogen                     │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Concomitant administration of bactrim (due to effects on creatinine)                                │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Concomitant administration of inhaled colistin for patients in the colistin PK arm as this will     │
│ create inaccuracies in colistin sputum concentration measurements                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Presence of a condition or abnormality that in the opinion of the investigator would compromise the │
│ safety of the patient or the quality of the data                                                    │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Inability to perform reproducible spirometry                                                        │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Documentation of CF diagnosis as evidenced by one or more clinical features consistent with the CF  │
│ phenotype and one or more of the following criteria                                                 │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Inability to expectorate sputum -                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                   │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛